Bictegravir & Lenacapavir: Promising New HIV Treatment Data

A new single-tablet combination of bictegravir and lenacapavir is showing promising results in the treatment of HIV-1, according to data presented at the upcoming February 22-25, 2026 Conference on Retroviruses and Opportunistic Infections (CROI) in Denver, Colorado. The investigational regimen, developed by Gilead Sciences, Inc., has met its primary endpoint in the Phase 3 ARTISTRY-1 trial, suggesting a potential new option for individuals living with HIV.

Addressing Complexity in HIV Treatment

Current HIV treatment often involves complex antiretroviral therapy (ART) regimens, which can require multiple pills taken at various times throughout the day. These regimens can negatively impact a patient’s quality of life and adherence to treatment. The ARTISTRY-1 trial specifically focused on individuals already virologically suppressed – meaning the virus was undetectable in their blood – but who were on such complex regimens. The goal was to determine if switching to a simpler, single-tablet combination would maintain viral suppression while improving convenience and potentially adherence.

ARTISTRY-1 Trial Results

The Phase 3 ARTISTRY-1 trial involved 128 participants randomly assigned to one of three groups: those receiving bictegravir (75mg) plus lenacapavir (25mg), those receiving bictegravir (75mg) plus lenacapavir (50mg) and a control group continuing their existing complex ART regimen. After 24 weeks, the results demonstrated a high degree of continued viral suppression. Specifically, HIV-1 RNA levels remained below 50 copies/mL in all but one participant (1.9%) in the bictegravir/lenacapavir 50mg group. No participants in either of the bictegravir/lenacapavir groups experienced viral rebound, compared to none in the control group.

Beyond maintaining viral suppression, the study also assessed the impact on CD4 cell counts, which are a key indicator of immune system health. CD4 cell counts remained stable across all three groups throughout the 24-week period. The median change from baseline in CD4 cell count was 18 cells/µL in the BIC 75mg + LEN 25mg group, -16 cells/µL in the BIC 75mg + LEN 50mg group, and 42 cells/µL in the complex ART group. Importantly, there were no study discontinuations due to serious adverse events in either of the bictegravir/lenacapavir groups.

Bictegravir and Lenacapavir: How They Work

Bictegravir is an integrase strand transfer inhibitor (INSTI), a class of drugs commonly used in HIV treatment. It works by blocking the viral enzyme integrase, which is essential for HIV to integrate its genetic material into the host cell’s DNA. Lenacapavir, is a first-in-class capsid inhibitor. It disrupts a different stage of the HIV life cycle by interfering with the formation of the viral capsid, a protective shell around the virus’s genetic material. Combining these two mechanisms of action may offer a more robust and durable antiviral effect.

Expanding HIV Prevention Options

Gilead’s presentation at CROI 2026 will also include updated data from the PURPOSE program, focusing on the use of lenacapavir for HIV prevention. Specifically, the data demonstrate the safety and efficacy of twice-yearly lenacapavir for pre-exposure prophylaxis (PrEP). This longer-acting formulation could significantly improve convenience and adherence for individuals at risk of HIV infection, potentially leading to increased uptake of PrEP.

Implications for the Future of HIV Treatment

The positive results from the ARTISTRY-1 trial and the ongoing data from the PURPOSE program suggest that bictegravir and lenacapavir have the potential to significantly impact the landscape of HIV treatment and prevention. The single-tablet combination offers a simplified regimen for those already on treatment, while the twice-yearly formulation of lenacapavir provides a new, convenient option for PrEP. Further evaluation of the bictegravir and lenacapavir combination is warranted to optimize treatment strategies for individuals with HIV who are currently receiving complex ART regimens.

These findings represent a step forward in the ongoing effort to improve the lives of people living with and at risk of HIV. The focus on expanding treatment and prevention options underscores the commitment to addressing the evolving needs of the HIV community.